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Abstract
Background: the classification criteria for primary Sjögren's syndrome (pSS) include a number of
oral components. In this study we evaluated if salivary flow and composition as well as dental caries
are oral markers of disease severity in pSS.
Methods: in 20 patients fulfilling the American-European Consensus criteria for pSS and 20 age-
matched healthy controls whole and parotid saliva flow rates and composition, measures of oral
dryness, scores of decayed, missing and filled tooth surfaces (DMFS), periodontal indices, oral
hygiene, and dietary habits were examined.
Results: in pSS, salivary flow rates, pH, and buffer capacities were lower, and DMFS, salivary
sodium and chloride concentrations higher than in the healthy controls. DMFS also correlated
inversely to salivary flow rates and positively to oral dryness. Apart from slightly increased gingival
index, and more frequent dental visits in pSS, the periodontal condition, oral hygiene or sugar
intake did not differ between these two groups. In pSS, findings were correlated to labial salivary
gland focus score (FS) and presence of serum-autoantibodies to SSA/SSB (AB). The patients having
both presence of AB and the highest FS (>2) also had the highest salivary sodium and chloride
concentrations, the lowest salivary phosphate concentrations, lowest salivary flow rates, and
highest DMFS compared to those with normal salivary concentrations of sodium and chloride at a
given flow rate.
Conclusion: the salivary changes observed in some pSS patients reflect impaired ductal salt
reabsorption, but unaffected acinar transport mechanisms, despite low salivary secretion. Our
results suggest that changes in salivary flow and composition as well as dental caries may serve as
potential markers of the extent of autoimmune-mediated salivary gland dysfunction in pSS. The
study also indicates that the ductal epithelium is functionally affected in some pSS patients, which
calls for future pathophysiological studies on the mechanisms underlying this impaired salt
reabsorption.
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Primary Sjögren's syndrome (pSS) is a common systemic
autoimmune disease that mainly affects middle-aged
women. The exact aetiology remains elusive, and appears
multifactorial. The disease is characterised by a chronic
periductal lymphocytic infiltration of the exocrine glands,
predominantly of the lacrimal and salivary glands. The
chronic inflammation is assumed to lead to glandular tis-
sue destruction, resulting in keratoconjunctivitis sicca and
hyposalivation and associated symptoms of ocular and
oral dryness [1,2].
The salivary dysfunction in pSS is of significant clinical
importance and may cause chronic oral discomfort as well
as compromised oropharyngeal functions [3-5]. Subse-
quently, the patients' well-being and oral health-related
quality of life are also impaired [5,6]. Cross-sectional
studies have shown that patients with pSS have a high car-
ies experience with lesions usually located on the cervical
surfaces of the teeth, as well as early dental loss due to car-
ies [3,7-10], despite good oral hygiene [11]. Dental caries,
which is a local, but also a multifactorial disease, arises
from a concerted action of the aetiological factor (dental
plaque) and determinants including salivary factors, med-
ication, systemic disease as well as behavioural factors
[12]. However, the selective significance of salivary factors
on dental caries in pSS remains an open question. In light
of the impaired saliva formation in pSS it is noteworthy
that an exact cut-off value for salivary flow and/or separate
salivary constituents predicting the risk of developing
dental caries has not yet been agreed on. In the diagnosis
of Sjögren's syndrome (SS), an unstimulated whole saliva
flow rate of ≤ 1.5 ml/15 min is currently considered path-
ological [13], but at this point the caries process may have
been going on for years revealed by the presence of a high
number of decayed, missed and filled teeth [3,7-10].
The American-European Consensus Classification Criteria
for pSS include evaluation of salivary gland dysfunction
by means of parotid sialography, salivary gland scintigra-
phy, whole saliva sialometry and labial salivary gland
biopsy as well as questionnaire concerning symptoms of
oral dryness [13]. The purpose of this study was to evalu-
ate parotid flow rate, whole and parotid saliva composi-
tion and dental caries as potential oral markers of disease
severity in patients with pSS. Thus we hypothesised that
patients with pSS exhibit specific changes in salivary flow
and composition due to presence of focal lymphocytic
infiltration in their labial salivary glands (FS) and/or
serum autoantibodies to Ro (SSA) and/or La (SSB) anti-
gens (AB) as compared to age- and gender-matched
healthy controls with normal salivary gland function. We
further hypothesised that in patients with pSS dental car-
ies is related to impaired salivary flow and associated
changes in saliva composition.
Methods
The study included 20 randomly selected patients with
pSS, who attended the Department of Oral Medicine, Uni-
versity of Copenhagen, for routine follow-up examina-
tions. They were diagnosed according to the Copenhagen
criteria, but also met the American-European Consensus
Classification Criteria for pSS [13,14]. All patients had
complaints of dry eyes and dry mouth according to the
questionnaire of the American-European classification
criteria [13] as well as evidence of keratoconjunctivitis
sicca. Eighteen patients had unstimulated whole saliva
flow rate (UWS) ≤ 1.5 ml/15 min. Two patients had UWS
>1.5 ml/15 min, but otherwise fulfilled the criteria. Four-
teen patients had a positive labial salivary gland biopsy
with focus score ≥ 1 as well as presence of AB. Among the
remaining 6 patients, 2 had FS, but not presence of AB,
and 4 patients had presence of AB, but not FS. The labial
salivary glands of the latter 4 patients displayed chronic
sialoadenitis where inflammatory cells were observed but
did not form any foci. In all 20 patients, estimation of the
presence of serum autoantibodies was performed within
the same timeframe as the saliva collections and the clin-
ical assessments. In 16 of these patients labial salivary
gland biopsies were performed at the same time. The
remaining 4 patients refused a labial salivary gland rebi-
opsy, as they had their diagnosis of pSS for 25, 23, 16 and
10 years, respectively.
In order to understand the underlying salivary pathophys-
iology in pSS, the study also included 20 healthy controls
selected among persons attending the Institute of Odon-
tology for dental treatment to obtain reference values of
normalcy. The selection was based on the requirements
that controls had no present or past medical history of sys-
temic disease, did not take any medication including con-
traceptives and hormonal replacement, had no current
use of tobacco products, and matched the pSS patients
with regard to age.
Clinical examination
One examiner (AMLP) conducted the whole saliva collec-
tions, interviews, and oral clinical examinations. About 2
hours after collection of whole saliva, another examiner
(AB) conducted collections of parotid saliva. In order to
minimize the influence of circadian cycle on salivary
secretion and composition all procedures were carried out
in the same order and at a fixed time of the day, i.e.
between 9.00 and 11.45 a.m. The local Danish Ethical
Committees approved the study protocol, and all partici-
pants completed an informed consent form according to
the Declaration of Helsinki. The number of decayed, miss-
ing and filled surfaces (DMFS) was recorded excluding
third molars as previously described in details [5]. Plaque
and gingival indices and periodontal probing pocket
depth were determined at four sites per tooth on six indexPage 2 of 13
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went a standardised interview including inquiries on
medical disease symptoms, dental history, dental visits,
medication, tobacco smoking, dietary (especially regard-
ing daily sugar intake) and oral hygiene habits. Further-
more, symptoms of oral dryness were assessed by means
of a categorised questionnaire (based on Beck's inventory
scale, item 9 [15]) with four degrees of severity (scores 0–
3), as previously described [8]).
Collection of whole and parotid saliva
Unstimulated whole saliva (UWS) and paraffin-stimu-
lated whole saliva (SWS) were sampled over a 15-min and
5-min period, respectively, as described previously [8].
Unstimulated parotid saliva (UPS) and stimulated
parotid saliva (SPS) were sampled over an average period
of 20 min and 5 min, respectively. A saliva collection set-
up impermeable to CO2 was used [16]. Stimulation of the
parotid saliva was initiated by applying 1 ml of 1% citric
acid to the dorsal part of the tongue every 15 sec. The flow
rate, given with 2 decimal places, was determined by
weighing the saliva-collecting cup, tube, and syringe
before and after saliva collection, and expressed as ml/
min [8]. The subjects were instructed to refrain from eat-
ing, drinking, smoking, and any oral hygiene for 2 h pre-
ceding the saliva sampling.
Sialochemical analysis
Concentrations (mM) of sodium, potassium and total cal-
cium were determined by atomic absorption spectroscopy
[16,17]. Concentrations (mM) of chloride were measured
by coulometric titration and total phosphate (mM) by the
molybdic reaction [16,17]. Total protein (µg/ml) was
measured by the Coomassie reaction. Amylase activity
(stated as the catalytic activity of the enzyme, i.e., kat =
mole/s and given in µkat/l, where one µkat/l corresponds
to 60 U/l) was measured by means of the Phadebas™ test
kit. Saliva was diluted 1000 times more than usually rec-
ommended for plasma by the test kit. The volume of
saliva required for complete sialochemical analysis was
240 µl corresponding to an average collection period for
UPS of less than 20 min and for SPS less than 5 min for
the pSS patients.
Parotid saliva pH, PCO2, buffer capacity, and saturation
with regard to hydroxyapatite Parotid saliva pH and PCO2
were determined on an ABL 605 blood gas analyser (Radi-
ometer™), and the HCO3- concentration was calculated
from the pH and Pco2 values as previously described [17].
The parotid saliva buffer capacity (β), which originated
from the HCO3- and phosphate buffer systems, was calcu-
lated individually for each saliva sample at the pH value
of the sample [18]. Briefly, the buffer capacity for each
buffer system was calculated as:
2.3 [C] * ([CB]/[C]) * (1-([CB]/[C]))
Where ([C]) states the total concentration of the buffer
system and ([CB]) states the concentration of the base in
the buffer system. The concentrations of the bases was cal-
culated as previously described [16] and the pK values
used for the bicarbonate and phosphate buffer systems
was 6.1 for carbonic acid [16,17] and 6.8 for H2PO4- [19].
The sums of calculated β from both the HCO3- and phos-
phate buffer systems are in this study denoted as saliva β.
At pH values above 5 (counting for all except one sample)
the contribution from the protein buffer system, relative
to the HCO3- and phosphate buffer systems, was consid-
ered negligible [16] and therefore not included in the
saliva β.
The degree of saturation (DSHAP) of saliva with respect to
hydroxyapatite, i.e. the calcium phosphate salt and main
mineral of the tooth tissues, was calculated according to
the method described by Schmidt-Nielsen [19]. The nega-
tive logarithm of the ionic product of hydroxyapatite
(pIHAP) was calculated from the saliva p [Ca2+], p [HPO42-
], and p [H+]. The negative logarithm of the solubility
product of hydroxyapatite (pSPHAP) was calculated by the
constant given by Schmidt-Nielsen [19] and the ionic
strength of each saliva sample. Given the relatively low
ionic strength of the saliva samples analysed (0.039 ±
0.020) we found this simple method for calculation of
DSHAP acceptable. Finally, the critical pH of parotid saliva,
i.e. the pH value at which saliva is saturated (i.e., neither
super- nor undersaturated) with respect to hydroxyapatite
(pIHAP equal to pSPHAP) was calculated.
Statistical analysis
Differences in the salivary and clinical parameters
between the patient and control groups were analysed by
Wilcoxon rank-sum test (categorised variables) and two-
sampled t-test (numerical variables). Fisher's test (less
than ten in one category) and the chi-squared test (more
than ten) were used for analysis of distributions between
the two groups. Associations between variables were ana-
lysed by the Spearman rank order correlation analysis (rs).
In order to find the best predictor for a given outcome,
multiple regression analysis was used with stepwise back-
ward elimination with the adjusted R-squared values
given. Significance was selected at a level of P ≤ 0.05.
Results
Clinical findings
Table 1 summarises some of the anamnestic data and
results of self-assessed oral dryness of the 20 female
patients with pSS and 20 age-matched healthy females
included in this study. Sixteen pSS patients were taking
prescribed medicines on a regularly daily basis. Seven of
these patients were taking medicines known to impairPage 3 of 13
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saliva [20]. These included antihistamines and antide-
pressants that cause reduction in salivary flow due to inhi-
bition of the muscarinic cholinergic receptors [21], and
blockers of β-adrenoceptors that lead to impaired protein
secretion [22]. However, none of these medicines are
known to cause specific changes in the inorganic salivary
composition. The 7 patients taking "xerogenic" medicines
all had symptoms of oral dryness and/or were diagnosed
as pSS with hyposalivation (n = 5) before their current
medication was commenced. We therefore found no sig-
nificant association between the intake of medicines,
including the number of medicines, the salivary flow
rates, focus scores, and serum autoantibodies. All the pSS
patients complained of dry mouth. In pSS, a significant
inverse correlation was found between scores of oral dry-
ness and the SWS (rs = -0.50, P = 0.025), but only a ten-
dency toward a relationship between the oral dryness and
UWS, UPS and SPS. On the other hand, in both groups as
a whole, displaying large variations in oral dryness and
salivary flow rates, the subjective measures were signifi-
cantly inversely correlated to UWS (rs = -0.83, P < 0.001),
SWS (rs = -0.81, P < 0.001), UPS (rs = -0.74, P < 0.001), and
SPS (rs = -0.77, P < 0.001).
The results of the clinical examination are shown in Table
2. In spite of the fact, that the patients brushed their teeth
with fluoride-containing toothpaste and visited their den-
tist more frequently than the healthy individuals (Table
1), they had a significantly higher number of decayed,
missed and filled teeth and a higher gingival index. No
significant differences were found between the two groups
in terms of plaque index (frequency distribution of
scores), the periodontal probing pocket depth or the reg-
ular daily use of dental floss and/or toothpicks. Apart
from avoiding acidic, spicy, crunchy and dry foods the
patients' dietary habits (including sugar intake) did not
differ from those of the healthy controls. Neither the time
since pSS diagnosis, nor the duration of disease symptoms
or the age, were correlated to the flow rates. Moreover,
plaque- and gingival indices as well as periodontal prob-
ing pocket depth were not correlated to the salivary flow
rates, time since pSS diagnosis, duration of disease symp-
toms, DMFS, or age. In the groups as a whole, however, a
positive association between the gingival index and age
was found (rs = 0.33, P = 0.04).
Salivary flow and composition
As shown in Tables 3 and 4, the pSS patients had signifi-
cantly lower UWS, SWS, UPS and SPS than the healthy
controls. All pSS patients and one single healthy individ-
ual (without symptoms or clinical signs of local or sys-
temic disease) had with UWS ≤ 0.10 ml/min and/or SWS
≤ 0.70 ml/min, which are the cut-off values for hyposali-
vation [13,25]. In 8, 11 and 5 patients, UWS, UPS and
SPS, respectively, were close to or equal to 0 ml/min. In
both the patient and control group UWS and SWS were
mutually correlated (rs = 0.79, P < 0.001 and rs = 0.45, P <
0.05, respectively), but only in pSS a mutual correlation
was obtained between UPS and SPS (rs = 0.74, P < 0.001).
In 10, 9, 13 and 7 cases, respectively, volume of UWS,
SWS, UPS and SPS samples from pSS patients were insuf-
ficient for full sialochemical assessment. In pSS, the con-
centrations of sodium were significantly higher in both
whole and parotid saliva as compared to the healthy
controls. Similar results were obtained for chloride con-
centrations (except for the UPS) (Tables 3 and 4). Regard-
Table 1: Anamnestic data and results of self-assessed oral dryness of the female patients with primary Sjögren's syndrome (pSS) and 
the female healthy controls. Results are given as number of patients or scores (yes/no) and as means ± SD.
pSS (n = 20) Healthy controls (n = 20) P-value
Age (years) 60 ± 15 56 ± 13 0.437a
Duration of disease (years)* 6 ± 7 0 NA
Duration of symptoms (years) 10 ± 7 0 NA
Xerogenic medicines (yes/no)† 7/13 0/20 NA
Smokers (yes/no)§ 5/15 0/20 NA
Cigarettes per day (smokers only)§ 7 (2–20) 0 NA
Tooth brushing (times per day) 3 ± 1 2 ± 1 0.001a
Dental floss and/or toothpicks daily (yes/no) 16/4 15/5 1.000b
Dental visits per year (number) 3 ± 1 2 ± 1 0.001a
Oral dryness (score 0/1/2/3) 0/3/4/13 20/0/0/0 <0.001b
* The time from established diagnosis to present examination. †Patients were interviewed regarding their intake of medicines. Their intake of 
xerogenic medicines included antidepressants, antihistamines and β-blocking agents [20]. §Patients were also interviewed regarding their smoking 
habits, since cigarette smoking has been shown to reduce the extent of labial salivary gland lymphocytic infiltration [23] and to have a negative 
impact on periodontal status. Smoking, however, has no impact on salivary flow or composition [24].
P-values obtained by a two-sample t-test (a) and Fisher exact test (b). NA; not analyzed.Page 4 of 13
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(potassium, total calcium and total phosphate) as well as
the organic components (total protein and amylase activ-
ity) no statistically significant differences were found
between the two groups. In order to test whether the
changes in sodium and chloride concentrations were
merely related to changes in salivary flow rates, the
patients and healthy controls were matched by their UPS
and SPS flow rates within the range of 0.01–1.00 ml/min.
Figures 1A and 1B illustrate that the pSS patients may be
divided into two subgroups. In one group of patients the
salt reabsorption pattern was similar to that of the healthy
controls, whereas another group displayed high concen-
trations of parotid sodium and chloride despite low
parotid flow rates.
The pH and bicarbonate concentration in parotid saliva
were significantly lower in the pSS patients as compared
to the healthy controls (Table 4). Subsequently, the pSS
patients also had a significantly reduced buffer capacity
(β) of UPS and a lower degree of saturation with regard to
hydroxyapatite (DSHAP) in their UPS than the controls. In
pSS, the pH in UPS was in fact only 0.1 pH units from
their critical pH. Overall, the salivary β and DSHAP were
reduced due to low pH, bicarbonate and phosphate con-
centrations. In pSS, PCO2 of SPS was lower than in that of
the healthy controls (P = 0.02). Nevertheless, at corre-
sponding parotid flow rates, be it stimulated or not, the
relations between the flow rates, the saliva pH and the
bicarbonate concentrations were similar to those of the
healthy controls (Fig. 1C and 1D). Also the concentra-
tions of potassium, total phosphate, total calcium and
total protein (Fig. 1E, F, G, and 1H) were similar to those
of the controls.
Determinants of DMFS
As shown in Table 2 the pSS patients had significantly
higher DMFS than the healthy controls (p < 0.001) due to
higher number of filled (51 ± 23) and missed (37 ± 35)
tooth surfaces than the controls (33 ± 19 and 15 ± 35,
respectively) (P < 0.05). Also the prevalence of dental
treatment, i.e. the number of filled surfaces relative to the
total number of present tooth surfaces, was significantly
higher in the patients (55 ± 27%) than in the controls (25
Table 2: Oral findings in the patients with primary Sjögren's syndrome (pSS) and the healthy controls. Results are given as number of 
patients or scores (yes/no) and in medians (ranges).
pSS (n = 20) Healthy controls (n = 20) P-value
No. of teeth 22 (6–28) 28 (0–28) 0.011a
DMFS* 83.0 (25–140) 43.0 (10–140) 0.001a
Distribution of D/M/FS 23/745/1020 14/305/662 <0.001b
Subjects with dentures (yes/no) 4/16 7/13 0.480c
Distribution of PI (no. of 0/1/2/3 scores) 245/179/54/2 244/152/60/0 0.272b
Distribution of GI (no. of 0/1/2/3 scores) 346/116/16/2 330/95/31/0 0.034b
Probing pocket depth (PPD, mm) 2 (1–4) 2 (1–3) 0.523a
*D/M/FS, decayed, missed, filled surfaces; PI, plaque index; GI, gingival index. P-values obtained by Wilcoxon rank sum test (a), Chi2- test (b), and 
Fisher exact test (c).
Table 3: Unstimulated (UWS) and stimulated (SWS) whole salivary flow rate and composition in the patients with primary Sjögren's 
syndrome (pSS, n = 20) and the healthy controls (n = 20). Results are given in median (range).
UWS SWS
pSS Healthy controls P-value pSS Healthy controls P-value
Flow rate (ml/min) 0.02 (0.00–0.23) (n = 20) 0.39 (0.06–1.10) (n = 20) <0.001 0.14 (0.01–1.66) (n = 20) 1.40 (0.54–2.82) (n = 20) <0.001
Na+ (mM) 12.0 (8.0–47.0) (n = 11) 8.0 (4.5–17.0) (n = 20) 0.008 16.0 (8.0–59.0) (n = 12) 10.3 (5.5–30.0) (n = 20) 0.020
K+ (mM) 22.2 (5.1–48.0) (n = 11) 21.9 (6.8–33.4) (n = 20) 0.536 21.6 (15.2–34.6) (n = 12) 22.0 (11.5–26.5) (n = 20) 0.533
Total calcium (mM) 2.0 (1.3–3.2) (n = 7) 1.7 (0.5–2.8) (n = 19) 0.285 1.3 (0.7–1.9) (n = 12) 1.3 (0.8–2.5) (n = 20) 0.558
Cl- (mM) 25.8 (16.0–62.0) (n = 10) 18.3 (5.2–26.0) (n = 19) 0.003 22.6 (13.5–58.6) (n = 11) 16.1 (10.5–28.6) (n = 20) 0.037
Total phosphate (mM) 6.0 (1.2–15.0) (n = 9) 6.8 (2.4–11.7) (n = 19) 0.961 4.4 (2.4–8.5) (n = 11) 4.1 (1.6–11.5) (n = 20) 0.606
Total protein (mg/ml) 3.00 (1.52–8.84) (n = 8) 3.29 (1.36–6.25) (n = 19) 0.560 3.50 (0.421–8.93) (n = 12) 3.04 (1.23–5.54) (n = 20) 0.491
Total protein output (mg/min) 0.210 (0.06–0.80) (n = 8) 1.09 (0.50–2.38) (n = 19) <0.001 0.95 (0.11–4.33) (n = 12) 3.88 (2.35–8.06) (n = 20) <0.001
Amylase activity (µkat/l) 365 (0–4500) (n = 10) 980 (0–8940) (n = 19) 0.155 1490 (0–4080) (n = 12) 2280 (0–5890) (n = 20) 0.199
P-value obtained by Wilcoxon's rank sum test.Page 5 of 13
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were obtained for the number of decayed surfaces
between the patients and controls.
Table 5 shows the explanatory power of the two sets of
variables exhibiting the highest explanatory power on
DMFS in the pooled patient and control groups, namely
complaints of oral dryness and the actual salivary flow
rates. The estimate states the theoretical expected increase
or decrease in DMFS upon an integer increase of the
explaining variables, i.e. one score of subjective oral dry-
ness or one ml of saliva. Furthermore, the subjects' age
were added to the analyses due to the well-known effect of
this variable upon the number of missing surfaces, which
was also found to be significant in this study (rs = 0.63, P
< 0.001). As shown DMFS increases with increasing age
(per year) and increasing complaints of oral dryness, but
decreases with increasing salivary flow rates.
In the pSS patients, regardless of their age, the complaint
of oral dryness, but not the actual salivary flow rate, was
associated with dental status (DMFS). The lack of signifi-
cant correlation between flow rate and DMFS may be
ascribed to the narrow window of flow rates in pSS. Scores
of oral dryness correlated significantly with the total
DMFS (rs = 0.53, P < 0.05) and the prevalence of dental
treatment (rs = 0.51, P < 0.05). In addition, the prevalence
of dental treatment increased with the duration of pSS (rs
= 0.49, P < 0.05), independently of the patient's age.
Salivary gland focus score, serum autoantibodies, salivary 
flow and composition
In the pSS group, the focus scores (which ranged from 0
to 4) were significantly inversely correlated to UWS (rs = -
0.53, P < 0.05), SWS (rs = -0.68, P < 0.01), SPS (rs = -0.57,
P < 0.01), but not to UPS. Focus scores were not correlated
to oral dryness, time since pSS diagnosis, and duration of
disease symptoms. It is noteworthy, however, that the
patient group exhibited large variability with regard to
time since diagnosis and age (Table 1). The number of
focus scores and presence of serum autoantibodies were
positively correlated to salivary concentrations of sodium
and chloride in SPS (rs = 0.61, P < 0.05 and rs = 0.71, P <
0.01). Although highly increased sodium and chloride
concentrations were found in UPS as well, the number of
observations was too small to generate statistical signifi-
cance due to the sample volumes that did not allow for
sialochemistry (Table 4). Results further revealed that pSS
patients with the lowest UWS (i.e., 0–0.05 ml/min) also
had the highest focus scores (mean focus score 2.3 vs. 0.7,
respectively, P < 0.05), presence of serum autoantibodies
(n = 14), highest concentrations of salivary sodium and
chloride, but lowest salivary concentrations of total phos-
phate compared to patients with UWS ≥ 0.05 ml/min.
Table 4: Unstimulated (UPS) and stimulated (SPS) parotid salivary flow rates, composition including pH, PCO2, buffer capacity, degree 
of saturation with regard to hydroxyapatite, and critical pH in the patients with primary Sjögren's syndrome (pSS, (n = 20)) and the 
healthy controls (n = 20). Results are given in medians (range).
UPS SPS
pSS Healthy controls P-value pSS Healthy controls P-value
Flow rate (ml/min/gland) 0.00* (0.00–0.04) (n = 20) 0.04 (0.00–0.13) (n = 20) <0.001 0.10 (0.00–0.87) (n = 20) 0.72 (0.17–1.57) (n = 20) <0.001
pH 5.5 (4.9–6.2) (n = 7) 6.1 (5.4–6.6) (n = 14) 0.008 6.8 (5.3–7.6) (n = 13) 7.1 (6.8–8.0) (n = 19) 0.020
PCO2 (KPa) 2.5 (2.1–4.8) (n = 7) 3.3 (0.5–7.9) (n = 14) 0.455 3.5 (1.4–7.5) (n = 13) 5.5 (0.3–10.0) (n = 19) 0.021
Na+ (mM) 7.0 (0.0–111.0) (n = 9) 0.0 (0.0–8.5) (n = 19) 0.002 15.5 (3.5–93.0) (n = 15) 7.5 (0.0–65.0) (n = 20) 0.034
K+ (mM) 24.5 (4.5–52.5) (n = 9) 29.0 (17.5–62.0) (n = 19) 0.209 26.5 (12.0–53.0) (n = 15) 23.0 (18.0–40.0) (n = 20) 0.689
Total calcium (mM) 1.0 (0.4–2.4) (n = 9) 1.0 (0.6–4.1) (n = 16) 0.887 1.1 (0.6–1.8) (n = 13) 0.8 (0.4–1.4) (n = 20) 0.008
Cl- (mM) 22.5 (5.0–100.5) (n = 9) 19.0 (12.0–43.0) (n = 19) 0.588 27.0 (12.5–94.0) (n = 14) 15.5 (9.0–59.0) (n = 20) 0.037
Bicarbonate (mM) 0.2 (0.0–0.8) (n = 8) 0.8 (0.1–3.5) (n = 14) 0.017 3.6 (0.1–26.8) (n = 12) 11.3 (3.8–43.9) (n = 19) 0.025
Total phosphate (mM) 5.6 (2.3–15.0) (n = 7) 9.3 (4.1–18.9) (n = 16) 0.066 6.1 (2.1–8.2) (n = 11) 5.2 (3.2–16.9) (n = 20) 0.577
Total protein (mg/ml) 1.11 (0.47–8.97) (n = 9) 2.02 (0.64–5.34) (n = 18) 0.316 1.33 (0.62–6.66) (n = 14) 1.60 (0.84–4.19) (n = 20) 0.589
Total protein output (mg/min) 0 (0–0.18) (n = 9) 0.07 (0–0.30) (n = 18) <0.001 0.13 (0–1.38) (n = 14) 1.30 (0.29–5.42) (n = 20) <0.001









β(mmol H+/l. pH unit) 1.2 (0.1–2.9) (n = 7) 4.0 (2.3–8.9) (n = 13) <0.001 4.4 (0.5–6.7) (n = 10) 5.2 (0.7–10.1) (n = 19) 0.171
DSHAP 1.4 (0.2–3.6) (n = 9) 3.1 (2.5–10.4) (n = 16) 0.001 7.3 (0.6–21.4) (n = 13) 10.0 (4.5–22.0) (n = 19) 0.372
Critical pH 5.4 (5.1–6.2) (n = 7) 5.3 (5.0–5.5) (n = 16) 0.413 5.5 (5.2–6.2) (n = 11) 5.7 (5.2–5.8) (n = 19) 0.611
The buffer capacity (β) was calculated from the bicarbonate and phosphate concentrations individually for each saliva sample at its pH value, DSHAP 
denotes the degree of saturation with regard to hydroxyapatite. P-value obtained by a Wilcoxon's rank sum test. * corresponds to mean value below 
0.01 ml/min.Page 6 of 13
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shows the saliva composition as a function of the parotid saliva flow rate (both unstimulated and stimulated) in patients with 
pSS (bold circles) and healthy age-matched controls (open circles). Lines were fitted by linear (a and b) or non-linear regression 
(c-h) depending on the best obtainable fit judged from the R-squared values with unbroken lines representing pSS and dotted 
lines the controls. Figures 1a and b illustrates that the pSS patients can be divided into two subgroups with regard to salt reab-
sorption. One group of patients follow the reabsorption pattern of the healthy controls, whereas the other group display high 
sodium and chloride concentrations despite low parotid flow rates indicating differences in the degree of glandular affection by 
the disease of the patients studied.Page 7 of 13
(page number not for citation purposes)
BMC Clinical Pathology 2005, 5:4 http://www.biomedcentral.com/1472-6890/5/4Pooling data of UPS and SPS for the pSS group allowed us
to compare profiles of the patients with high sodium and
chloride concentrations to those with low ones. The
results of this analysis revealed that pSS with more than
40 mM sodium in their parotid saliva also had signifi-
cantly higher focus scores as well as presence of serum
autoantibodies, than pSS patients below this value (P <
0.01). The former also tended to have lower parotid flow
rates, more decayed tooth surfaces and to be younger than
the other pSS patients.
Discussion
Oral dryness and reduced salivary flow rates are some of
the most predominant and troubling oral sequelae of pSS.
This discussion focuses on the hypothesis if impaired sal-
ivary flow and/or composition and high caries experience
may serve as potential markers of disease severity in pSS.
Caries experience, oral hygiene, and salivary flow rates
The present study confirms the results of previous cross-
sectional studies showing that pSS patients have a signifi-
cantly higher DMFS compared to healthy controls, despite
the fact that these patients often have a good oral hygiene
and frequent dental follow-up visits [5,9,10]. When com-
paring SS patients with patients suffering from other
immune diseases and patients with xerostomia of other
origins, Boutsi et al. [26] found no significant differences
in the number of decayed, missed or filled teeth. In
accordance with our results, the SS patients were charac-
terised by having lower salivary flow rates, better oral
hygiene habits, slightly higher gingival scores, but similar
plaque scores, compared to the other groups [26]. Regard-
ing the other periodontal measures, our results support
those of previous studies showing that presence of perio-
dontal disease is not substantially increased in pSS [2,26].
The slightly increased gingival scores could be explained
by altered inflammatory response probably due to hor-
monal changes [27]. It has been reported that pSS patients
harbour lower numbers of periopathogenic microorgan-
isms than healthy controls [28]. In contrast, and despite a
good oral hygiene, pSS patients appear to harbour higher
numbers of cariogenic and acidophilic microorganisms
such as Streptococcus mutans and Lactobacillus species than
healthy controls [11]. Similar relationships between low
salivary flow rates and increased Lactobacillus counts
have also been observed in patients with hyposalivation
of other origins [29]. Thus, impaired salivary flow and
changes in saliva composition as seen in pSS are assumed
to favour a more aciduric oral microflora manifested by
an increased incidence of caries and fungal infections
[28]. At low flow rates, the bicarbonate concentration,
pH, and buffer capacity as well as the clearance of micro-
organisms and dietary sugars in the oral cavity generally
decrease [29], thereby promoting an environment domi-
nated by these oral pathogens and prolonged exposure of
dietary sugars to the teeth. In pSS patients with severely
reduced salivary flow rates the shift in the oral microflora
appears to occur despite a good oral hygiene. In addition,
the high number of microbial retention sites generated by
dental restorations such as fillings, crowns and bridges
found in pSS patients may contribute to the shift in oral
microflora [28] and complicate the maintenance of suffi-
cient oral hygiene procedures.
In accordance with previous studies we found that the
DMFS score is inversely correlated to salivary flow rates
and especially the unstimulated whole saliva flow rate
[8,10]. However, it has not yet been possible to identify a
cut-off value for salivary flow rate that can predict the risk
of developing dental caries, as caries is a multifactorial dis-
ease. In this study, 90% of the patients had UWS flow rates
below 0.10 ml/min, but as this value is merely a part of
Table 5: Explanatory power of age as well as subjective and objective salivary variables on DMFS in the patient group and control 
group all together (n = 40).
Estimate for DMFS SD for DMFS estimate Adjusted R-squared P-value
Subjective model
Age 1.4 0.4 0.26 <0.001
+ oral dryness 
questionnaire
11.1 2.3 0.53 <0.001
Objective model
Age 1.4 0.4 0.26 <0.001
+ UWS -57.4 20.7 0.37 <0.001
+ SWS -28.9 9.4 0.49 <0.001
+ UPS -499.2 173.0 0.57 <0.001
Estimate, SD, adjusted R-squared, and P-value obtained by multiple regression analysis. The estimate states the increase or decrease in DMFS upon 
addition of the explaining variables (age + oral dryness, or + UWS, SWS, and UPS) by an integer (one year, score, or ml). Since complaints of oral 
dryness and salivary flow demonstrated strong interrelations they could not be included in the same analysis. As shown age in combination with 
complaints of oral dryness explained 53% of the variance in DMFS, and age combined with salivary flow rates explained 57%.Page 8 of 13
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reflect the point at which caries is likely to develop. It has
been suggested that salivary flow rates up to 0.16 ml/min,
which include most pSS patients, may result in oral candi-
diasis [31] and increased development of experimental
caries [29]. Meanwhile, the onset of increased caries activ-
ity in pSS remains unclear. It has been stated that in
patients with SS, loss of teeth due to caries precede the first
symptom of xerostomia by on average 9 years [10].
Changes in salivary flow and composition, and subse-
quently development of caries, appear to precede the
symptom of oral dryness by several years. Increased caries
activity that cannot be explained by changes in habits
related to oral hygiene or diet may therefore represent a
useful clinical feature to suspect early pSS in women with-
out complaints of oral dryness, or intake of xerogenic
medications. In contrast to the uncertainty pertaining to
the onset of pSS and the initial consequences in terms of
increased caries lesions, the future perspectives on the
patients' dental health seem gloomy without professional
preventive intervention. In accordance with the observa-
tion that past caries experience is one of the best predic-
tors for future caries [32,33], the pSS patients in this study
have a much higher risk of developing future caries and
ultimately to loose teeth than the control group. Accord-
ingly, these patients should receive an individual dental
care programme in terms of oral hygiene instructions,
professional oral hygiene regimens, fluoride treatment,
dietary supervision and frequent dental follow-up visits in
order to prevent accelerated caries development.
Self-assessment of oral dryness
In healthy subjects, the sensation of oral dryness usually
occurs when whole saliva flow rate is reduced with more
than 50% [34]. In this study, all patients had complaints
of dry mouth and also substantially decreased salivary
flow rates, whereas the healthy controls had no dry mouth
complaints and in general, salivary flow rates within the
normal range [35].
Nonetheless, in pSS, the scores of oral dryness were only
inversely correlated to SWS, which may reflect a larger
span of SWS values than of UWS. We have previously
found an inverse correlation between scores of oral
dryness and UWS [8]. In the present study, the patients
had symptoms of oral dryness median 10 years prior to
the diagnosis of pSS. Symptoms of oral dryness in
combination with the participants' age could explain
about half of the variance in DMFS (Table 5). The
questionnaire may therefore not only be helpful in assess-
ing the intensity of oral dryness but also in identifying
patients with high DMFS.
Saliva pH and buffer capacity
The ability of human saliva to buffer acids is essential for
maintaining pH values in the oral environment above the
critical pH for hydroxyapatite (HAP), thereby protecting
the teeth against demineralisation. The buffer systems
responsible for the human saliva buffer capacity include
the bicarbonate, phosphate and protein systems [17,36-
38]. In normalcy, where the pH ranges from 6.0 to 7.5, the
bicarbonate and phosphate buffer systems are by far the
dominant ones having optimal buffering capacity at their
pK values of 6.1 and 6.8, respectively [16,19], whereas the
proteins have some effect on the buffer capacity at acidic
pH values below 5 [16,38].
In this study, the parotid saliva buffer capacity was calcu-
lated individually for each pSS patient and healthy control
based on the saliva bicarbonate and phosphate concentra-
tions at the respective saliva pH values. This calculation
gives an estimate of the buffer capacity of the saliva at the
time it is secreted from the parotid gland. In the pSS
patients, the buffer capacity of UPS was significantly lower
than in the healthy controls, mainly due to the low pH
value and bicarbonate concentration in saliva caused by
the low flow rates. Moreover, in pSS most of the pH values
of UPS were below the relevant pK values of both the
bicarbonate and phosphate buffer systems. As compared
to healthy controls, the pSS patients will therefore experi-
ence far more abundant pH drops in their saliva if
exposed to acidic challenges leading to a higher risk of
tooth demineralisation. Apart from a low buffer capacity,
and thereby impaired ability to maintain a non-acidic
saliva pH, the pSS patients also had a significantly lower
degree of saturation with respect to HAP in their saliva
(Table 4). Thus, in pSS, the mean pH of UPS was only one
tenth of a pH unit above their mean critical pH. This
implies that even a minor drop in pH will lead to under-
saturation of their saliva with respect to HAP and result in
either caries lesions or erosive damage to the teeth
depending on the origin of the acidic challenge.
Salivary bicarbonate and phosphate
Despite the differences between pSS patients and healthy
controls in sodium and chloride concentrations at compa-
rable low flow rates, stimulated or not, the HCO3- concen-
tration and saliva pH did not differ between the two
groups (Fig. 1A–D). The transport of bicarbonate in the
salivary glands is believed to occur via chloride/bicarbo-
nate exchange mechanisms [39]. The concentration of
bicarbonate in saliva is a consequence of the metabolic
CO2 -turnover in the salivary glands. CO2 freely diffuses
across the epithelial boundaries, and due to the presence
of carbonic anhydrase, the partial pressure for CO2 and
pH in the glandular compartments governs how much of
bicarbonate buffer system is present in form of HCO3- in
the saliva. The duct epithelium has dual functions withPage 9 of 13
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sorb (at low secretion rates) and secrete (at high secretion
rates due to increased metabolic turnover of the gland).
This study demonstrated a tendency towards lower total
phosphate concentrations in pSS patients than in healthy
controls. Previous studies have found significantly
reduced phosphate concentrations in stimulated parotid
and SM/SL saliva of patients with SS compared to healthy
controls and patients with conditions resembling SS [40-
42]. It should be stressed that the mechanism behind
phosphate transport in human salivary gland tissues has
not yet been fully characterised. It probably includes an
acinar secretion and/or a ductal reabsorption via sodium-
phosphate co-transport mechanism as that observed in
the renal proximal tubules [43].
Salivary sodium and chloride
Our sialochemical results are interpreted within the frame
of the classical two-stage model of saliva formation [44].
Under normal physiological conditions, and in response
to nervous stimuli, the acinar cells produce primary saliva,
which has an ionic composition resembling that of
plasma. As the primary saliva passes through the duct sys-
tem it becomes modified by reabsorption of sodium and
chloride (but without water due to the low water permea-
bility) whereby the final saliva secreted into the oral cavity
becomes hypotonic with sodium and chloride concentra-
tions much below that of the original primary saliva. The
composition of the final saliva secreted into the oral cavity
strongly depends on the secretion rate in such a way that
at low flow rates the saliva contains low sodium and chlo-
ride concentrations and as the flow rates increase the con-
centrations of sodium and chloride will rise. This normal
physiological relation between parotid flow rate and
sodium and chloride concentrations was seen in the
healthy controls and in some of the pSS patients (0.01–
1.00 ml/min) as well (Fig. 1A and 1B). However, for other
pSS patients with flow rates within the same frame,
another picture emerged, since their sodium and chloride
concentrations were remarkably higher than normally
whether stimulated or not. Thus, on a group basis the pSS
patients have significantly higher concentrations of
sodium and chloride than the healthy controls (Table 4).
This finding is in accordance with several previous studies
on whole saliva, parotid and submandibular/sublingual
saliva (SM/SL) [5,40-42,45,46]. The concentrations of
sodium and chloride have also been shown to be higher
in SM/SL of patients with pSS and secondary SS compared
to patients with clinical conditions resembling SS, i.e.,
sialoadenosis, sodium retention dysfunction syndrome
and medication-induced xerostomia [42]. Overall, these
compositional changes appear to be unique for some pSS
patients. It has been stated that SM/SL glands are affected
earlier by SS than the parotid glands due to an average
reduction of stimulated SM/SL flow rate preceding that of
the stimulated parotid flow rate [40,42]. On the other
hand, cut-off values for sodium, chloride and phosphate
in SPS and stimulated SM/SL being predictive for SS
demonstrated almost similar specificity (69 and 71%,
respectively) and sensitivity (81%) [32].
Other salivary constituents
Despite the low salivary flow rates seen in the pSS, the aci-
nar transport mechanisms involved in the formation of
primary saliva seem to be unaffected by the glandular
lymphocytic infiltration. Accordingly, concentrations of
potassium, total calcium, total protein and amylase activ-
ity in whole and parotid saliva did not differ from those
of the healthy controls, which is in agreement with previ-
ous reports [40,45]. Furthermore, it has been shown that
the output of statherin and acidic proline-rich proteins,
which reflect the secretion of selected parotid proteins,
did not differ between pSS patients and healthy controls
[5]. Normal concentrations of total calcium, total protein
and levels of amylase activity indicate that the remaining
functional acinar cells are capable of synthesis and secre-
tion of primary saliva with normal composition despite
the marked lymphocytic infiltration and structural
changes.
Impaired in ductal salt reabsorption reflects disease 
severity in pSS
The changes in salivary composition indicate that the duct
epithelium, and mainly the striated duct epithelium, can-
not effectively reabsorb the high concentrations of
sodium and chloride of the primary saliva in some of the
pSS patients, despite low salivary flow rates. The pSS
patients who exhibited high concentrations of sodium
and chloride were also characterised by having the lowest
flow rates, the highest focus score (FS) and highest con-
centrations of serum autoantibodies (AB) in addition to a
tendency of being younger than the pSS patients with nor-
mal salivary concentrations of sodium and chloride.
Overall, the subgroup of pSS patients with the highest
concentrations of salivary sodium and chloride and low-
est total phosphate concentrations appeared to be more
severely affected by pSS having more exocrine and non-
exocrine disease manifestations than those without these
salivary changes supporting previous observations [5]. It
should be stressed that there was no relationship between
reduced salivary flow and compositional changes and
intake of medications. The question is whether the sub-
group of patients with normal salivary concentrations of
sodium and chloride and some preserved salivary gland
function has a late onset of pSS or a "milder" glandular
response to autoimmunity compared to the subgroup
with high salivary sodium and chloride concentrations or
salivary secretion close to or equal to 0 ml/min. Another
relevant question is whether the latter subgroup ofPage 10 of 13
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lymphoma. The results of our study therefore need to be
tested in a large prospective cohort study and compared
with group of patients with non-immunological destruc-
tion of their salivary glands in order to validate the use of
specific salivary changes and dental caries as markers of
salivary gland dysfunctional severity/disease severity in
pSS. At present there is no international expert consensus
regarding measures for assessment of disease activity,
severity, damage or outcome in pSS that can be used in the
evaluation of clinical trials of new therapies and longitu-
dinal observational studies. Recent reports, however, indi-
cate that the development and evaluation of such
measures has begun [47,48].
In pSS, the salivary gland histopathology is characterised
by periductal lymphocytic infiltration and acinar destruc-
tion. The duct epithelium, however, appears relatively
unaffected by the lymphocytic infiltration, which con-
trasts the observed salivary changes in pSS. On the other
hand, the discrepancy may be explained by morphologi-
cal differences between the labial salivary glands, which
predominantly consist of mucous acini and have a very
short duct system, and the parotid glands, which comprise
serous acini and have long duct system. Nevertheless, it
has been stated that the histopathological changes of the
labial salivary glands mimic those of the parotid glands
[49,50]. It has been suggested that Bcl-2 positive basal
cells of striated/excretory ducts possess an extensive capac-
ity for pluridirectional morphogenetic differentiation
[51]. On this basis, it could be speculated that the duct
cells in some pSS patients possess antigenic properties,
which initiate an autoimmune response that could be
associated with morphogenesis and cell differentiation of
the salivary gland tissues. It has not yet been possible to
identify a specific anti-salivary duct antibody in pSS that is
capable of inhibiting cell differentiation. Our finding of
more pronounced acinar and ductal tissue functional
impairment in pSS patients with both FS and AB, than in
patients with FS or AB, supports the idea that circulating
autoantibodies or inflammatory mediators produced
locally by the inflammatory cells, interfere with the neural
release of neurotransmitter substances or interact with the
binding of neurotransmitters to receptors on the cell sur-
face, thereby impairing the acinar secretion and/or the
ductal reabsorptive modification of saliva [2]. Along this
line, an in vitro study on isolated human acini and duct
segments from pSS patients have shown that these cells
possess functional receptor systems and normal response
in changes in the intracellular free calcium concentration
upon maximal secretagogue stimulation [52]. The fact
that the ductal uptake of sodium via amiloride-sensitive
epithelial sodium channel (ENaC) is regulated by circulat-
ing adrenal mineralocorticoids, e.g. aldosterone [53]
could also indicate that some pSS patients have low levels
of aldosterone. However, this still needs to be clarified.
Conclusion
The results of this study indicate that specific sialometric
and sialochemical glandular changes, particularly changes
in sodium and chloride concentrations, may serve as oral
markers of disease severity in pSS. The question arises
whether pSS represents a continuum of patients with dif-
ferent stages of disease/affection of salivary glands or dif-
ferent diseases affecting the salivary gland tissues. There is
great need of disease assessment and outcome markers in
pSS. The hypotheses generated from our results on
changes in salivary flow and composition as well as high
caries experience as potential markers of the extent of
autoimmune-mediated salivary gland dysfunction in pSS
therefore need to be tested in a large prospective cohort
study including patients with early to long-standing dis-
ease. In addition, the mechanisms underlying the
impaired ductal salt reabsorption observed in the pSS
patients with presence of both labial salivary gland focus
score and serum-autoantibodies need to be further eluci-
dated in future pathophysiological studies.
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